• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

medRxiv 和 PubMed 上的 COVID-19 随机对照试验。

COVID-19 randomized controlled trials in medRxiv and PubMed.

机构信息

Hospital Care Research Unit, Hyogo Prefectural Amagasaki General Medical Center, Higashinaniwa-cho 2-17-77, Amagasaki 660-8550 Japan; Department of Community Medicine in the Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan; Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan; Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Higashinaniwa-cho 2-17-77, Amagasaki 660-8550 Japan.

Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan; Department of Gynecology, Women's Center, Yotsuya Medical Cube, 7-7, Nibancho, Chiyoda-ku, Tokyo 102-0084, Japan.

出版信息

Eur J Intern Med. 2020 Nov;81:97-99. doi: 10.1016/j.ejim.2020.09.019. Epub 2020 Sep 22.

DOI:10.1016/j.ejim.2020.09.019
PMID:32981802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7508503/
Abstract

• This study investigated the difference between COVID-19 RCT in medRxiv and in PubMed. • SPIN in the conclusion was more frequently seen in reports in medRxiv than PubMed. • Readers should pay attention to the overstatements in preprints of COVID-19 RCT.

摘要

• 本研究调查了 medRxiv 和 PubMed 中 COVID-19 RCT 的差异。 • medRxiv 中的报告比 PubMed 中更频繁地出现结论中的 SPIN。 • 读者应注意 COVID-19 RCT 预印本中的夸大陈述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a9/7508503/64e7784172e9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a9/7508503/64e7784172e9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2a9/7508503/64e7784172e9/gr1_lrg.jpg

相似文献

1
COVID-19 randomized controlled trials in medRxiv and PubMed.medRxiv 和 PubMed 上的 COVID-19 随机对照试验。
Eur J Intern Med. 2020 Nov;81:97-99. doi: 10.1016/j.ejim.2020.09.019. Epub 2020 Sep 22.
2
Randomized  Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative.新冠疫情时代的随机对照试验与真实世界数据：一种错误的说法。
Cancer Invest. 2020 Nov;38(10):537-542. doi: 10.1080/07357907.2020.1841922. Epub 2020 Nov 5.
3
Randomized Clinical Trials and COVID-19: Managing Expectations.随机临床试验与 COVID-19：合理期待管理
JAMA. 2020 Jun 9;323(22):2262-2263. doi: 10.1001/jama.2020.8115.
4
Scientific Rigor in the Age of COVID-19.新冠疫情时代的科学严谨性
JAMA Oncol. 2021 Feb 1;7(2):171-172. doi: 10.1001/jamaoncol.2020.6639.
5
Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic.关于 COVID-19 大流行的学术出版物、预印本和注册临床试验的特征。
PLoS One. 2020 Oct 6;15(10):e0240123. doi: 10.1371/journal.pone.0240123. eCollection 2020.
6
Covid-19 vaccine trial protocols released.新冠疫苗试验方案已公布。
BMJ. 2020 Oct 21;371:m4058. doi: 10.1136/bmj.m4058.
7
Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence.新冠病毒肺炎中的抗凝治疗：随机试验应在热情与证据之间找到平衡。
Thromb Res. 2020 Dec;196:638-640. doi: 10.1016/j.thromres.2020.09.033. Epub 2020 Oct 8.
8
Covid-19: What happened to randomised controlled trials?新冠疫情：随机对照试验怎么了？
BMJ. 2021 Feb 11;372:n387. doi: 10.1136/bmj.n387.
9
The WHO's chief scientist on a year of loss and learning.世界卫生组织首席科学家谈损失与收获的一年。
Nature. 2020 Dec;588(7839):583-585. doi: 10.1038/d41586-020-03556-y.
10
COVID-19: Pitfalls in Offering Research Participation as Therapy in Clinical Settings.新型冠状病毒肺炎：在临床环境中将研究参与作为治疗手段的陷阱。
J Gen Intern Med. 2020 Nov;35(11):3359-3360. doi: 10.1007/s11606-020-06158-6. Epub 2020 Sep 3.

引用本文的文献

1
SARS-CoV-2 infection risk by non-healthcare occupations: a systematic review and meta-analysis.非医疗职业的新冠病毒感染风险：一项系统综述与荟萃分析
J Occup Med Toxicol. 2025 May 22;20(1):17. doi: 10.1186/s12995-025-00462-9.
2
Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review.新冠病毒19临床试验预印本与已发表报告的一致性及其对决策的影响：回顾性审查
BMJ Med. 2022 Oct 3;1(1):e000309. doi: 10.1136/bmjmed-2022-000309. eCollection 2022.
3
The Impact of COVID-19 Pandemics on the Development of Health Risk Communication: Challenges and Opportunities.

本文引用的文献

1
Guideline-Based Chinese Herbal Medicine Treatment Plus Standard Care for Severe Coronavirus Disease 2019 (G-CHAMPS): Evidence From China.基于指南的中药治疗加标准护理方案用于重症新型冠状病毒肺炎（G-CHAMPS）：来自中国的证据
Front Med (Lausanne). 2020 May 27;7:256. doi: 10.3389/fmed.2020.00256. eCollection 2020.
2
Keeping up with studies on covid-19: systematic search strategies and resources.紧跟新冠病毒相关研究：系统检索策略与资源
BMJ. 2020 Apr 23;369:m1601. doi: 10.1136/bmj.m1601.
3
RoB 2: a revised tool for assessing risk of bias in randomised trials.
新冠疫情对健康风险沟通发展的影响：挑战与机遇。
Int J Environ Res Public Health. 2022 Dec 30;20(1):645. doi: 10.3390/ijerph20010645.
4
Transparency and reporting characteristics of COVID-19 randomized controlled trials.COVID-19 随机对照试验的透明度和报告特征。
BMC Med. 2022 Sep 26;20(1):363. doi: 10.1186/s12916-022-02567-y.
5
From registration, protocol to report: are COVID-19-related RCTs in mainland China consistent? A systematic review of clinical trial registry and literature.从注册、方案到报告：中国大陆的 COVID-19 相关 RCT 是否一致？一项临床试验注册库和文献的系统评价。
BMJ Open. 2022 Jul 21;12(7):e058070. doi: 10.1136/bmjopen-2021-058070.
6
Tracking changes between preprint posting and journal publication during a pandemic.追踪大流行期间预印本发布和期刊出版之间的变化。
PLoS Biol. 2022 Feb 1;20(2):e3001285. doi: 10.1371/journal.pbio.3001285. eCollection 2022 Feb.
7
Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation.新冠病毒研究的预印本和最终期刊出版物的横断面研究：结果报告的差异和解读的倾向性。
BMJ Open. 2021 Jul 16;11(7):e051821. doi: 10.1136/bmjopen-2021-051821.
8
Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan.为什么在大流行期间参与国际临床试验平台很重要？在日本启动REMAP-CAP。
J Intensive Care. 2021 Apr 14;9(1):34. doi: 10.1186/s40560-021-00547-7.
《随机对照试验偏倚风险评估工具2：修订版》
BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898.
4
Guidelines for reporting meta-epidemiological methodology research.报告元流行病学方法学研究的指南。
Evid Based Med. 2017 Aug;22(4):139-142. doi: 10.1136/ebmed-2017-110713. Epub 2017 Jul 12.
5
Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes.主要结局为统计学无显著性结果的随机对照试验的报告和解释。
JAMA. 2010 May 26;303(20):2058-64. doi: 10.1001/jama.2010.651.